A ninth product candidate in our generics pipeline is ranolazine extended-release tablets. It is a generic version of the marketed drug Ranexa®. This product is currently the subject of an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA) and is available for partnering.
Ranolazine is a is an anti-anginal medication indicated for the treatment of chronic angina. According to Symphony Health Solutions, U.S. sales for the 12 months ending Janaury 2017 for Ranexa® were approximately $867 million (TRx MBS Dollars).